Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: A Children's Oncology Group Report

Stanton Goldman; Lynette Smith; Paul Galardy; Sherrie L. Perkins; John Kimble Frazer; Warren Sanger; James R. Anderson; Thomas G. Gross; Howard Weinstein; Lauren Harrison; Bruce Shiramizu; Matthew Barth; Mitchell S. Cairo

doi:10.1111/bjh.13040

Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: A Children's Oncology Group Report

Stanton Goldman, Lynette Smith, Paul Galardy, Sherrie L. Perkins, John Kimble Frazer, Warren Sanger, James R. Anderson, Thomas G. Gross, Howard Weinstein, Lauren Harrison, Bruce Shiramizu, Matthew Barth, Mitchell S. Cairo

Pediatric and Adolescent Medicine

Research output: Contribution to journal › Article › peer-review

89 Scopus citations

Abstract

Children and adolescents with Burkitt Lymphoma (BL) and combined central nervous system (CNS) and bone marrow involvement still have a poor prognosis with chemotherapy alone. We therefore investigated in children and adolescents with bone marrow (≥25% blasts) and/or CNS-positive Burkitt lymphoma the chemoimmunotherapy combination of rituximab (375 mg/m²) and the standard chemotherapy arm of our previously reported French-American-British (FAB) Lymphome Malins de Burkitt (LMB) 96 trial. Central pathological and cytogenetic characterization was also performed. There were 40 evaluable patients with Burkitt histology (25 with leukaemia and 15 with CNS disease ± leukaemia). The chemoimmunotherapy regimen was well tolerated. The incidence of grade III/IV mucositis during induction cycles with combined chemotherapy and rituximab was 31% and 26%, respectively. The 3-year event-free survival (EFS)/overall survival (OS) was 90% (95% confidence interval [CI], 76-96%) in the entire cohort and 93% (95% CI, 61-99%) in patients with CNS disease. Based on the results of this trial, an international randomized study of FAB/LMB 96 chemotherapy ± rituximab for high-risk patients is currently under investigation.

Original language	English (US)
Pages (from-to)	394-401
Number of pages	8
Journal	British journal of haematology
Volume	167
Issue number	3
DOIs	https://doi.org/10.1111/bjh.13040
State	Published - Nov 1 2014

Keywords

Burkitt leukaemia
Burkitt lymphoma
Chemotherapy
Children
Rituximab

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.13040

Cite this

Goldman, S., Smith, L., Galardy, P., Perkins, S. L., Frazer, J. K., Sanger, W., Anderson, J. R., Gross, T. G., Weinstein, H., Harrison, L., Shiramizu, B., Barth, M., & Cairo, M. S. (2014). Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: A Children's Oncology Group Report. British journal of haematology, 167(3), 394-401. https://doi.org/10.1111/bjh.13040

Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: A Children's Oncology Group Report. / Goldman, Stanton; Smith, Lynette; Galardy, Paul et al.
In: British journal of haematology, Vol. 167, No. 3, 01.11.2014, p. 394-401.

Research output: Contribution to journal › Article › peer-review

Goldman, S, Smith, L, Galardy, P, Perkins, SL, Frazer, JK, Sanger, W, Anderson, JR, Gross, TG, Weinstein, H, Harrison, L, Shiramizu, B, Barth, M & Cairo, MS 2014, 'Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: A Children's Oncology Group Report', British journal of haematology, vol. 167, no. 3, pp. 394-401. https://doi.org/10.1111/bjh.13040

@article{8367eea272544747b31bc9f7b7728c89,

title = "Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: A Children's Oncology Group Report",

abstract = "Children and adolescents with Burkitt Lymphoma (BL) and combined central nervous system (CNS) and bone marrow involvement still have a poor prognosis with chemotherapy alone. We therefore investigated in children and adolescents with bone marrow (≥25% blasts) and/or CNS-positive Burkitt lymphoma the chemoimmunotherapy combination of rituximab (375 mg/m2) and the standard chemotherapy arm of our previously reported French-American-British (FAB) Lymphome Malins de Burkitt (LMB) 96 trial. Central pathological and cytogenetic characterization was also performed. There were 40 evaluable patients with Burkitt histology (25 with leukaemia and 15 with CNS disease ± leukaemia). The chemoimmunotherapy regimen was well tolerated. The incidence of grade III/IV mucositis during induction cycles with combined chemotherapy and rituximab was 31% and 26%, respectively. The 3-year event-free survival (EFS)/overall survival (OS) was 90% (95% confidence interval [CI], 76-96%) in the entire cohort and 93% (95% CI, 61-99%) in patients with CNS disease. Based on the results of this trial, an international randomized study of FAB/LMB 96 chemotherapy ± rituximab for high-risk patients is currently under investigation.",

keywords = "Burkitt leukaemia, Burkitt lymphoma, Chemotherapy, Children, Rituximab",

author = "Stanton Goldman and Lynette Smith and Paul Galardy and Perkins, {Sherrie L.} and Frazer, {John Kimble} and Warren Sanger and Anderson, {James R.} and Gross, {Thomas G.} and Howard Weinstein and Lauren Harrison and Bruce Shiramizu and Matthew Barth and Cairo, {Mitchell S.}",

note = "Publisher Copyright: {\textcopyright} 2014 John Wiley & Sons Ltd.",

year = "2014",

month = nov,

day = "1",

doi = "10.1111/bjh.13040",

language = "English (US)",

volume = "167",

pages = "394--401",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia

T2 - A Children's Oncology Group Report

AU - Goldman, Stanton

AU - Smith, Lynette

AU - Galardy, Paul

AU - Perkins, Sherrie L.

AU - Frazer, John Kimble

AU - Sanger, Warren

AU - Anderson, James R.

AU - Gross, Thomas G.

AU - Weinstein, Howard

AU - Harrison, Lauren

AU - Shiramizu, Bruce

AU - Barth, Matthew

AU - Cairo, Mitchell S.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Children and adolescents with Burkitt Lymphoma (BL) and combined central nervous system (CNS) and bone marrow involvement still have a poor prognosis with chemotherapy alone. We therefore investigated in children and adolescents with bone marrow (≥25% blasts) and/or CNS-positive Burkitt lymphoma the chemoimmunotherapy combination of rituximab (375 mg/m2) and the standard chemotherapy arm of our previously reported French-American-British (FAB) Lymphome Malins de Burkitt (LMB) 96 trial. Central pathological and cytogenetic characterization was also performed. There were 40 evaluable patients with Burkitt histology (25 with leukaemia and 15 with CNS disease ± leukaemia). The chemoimmunotherapy regimen was well tolerated. The incidence of grade III/IV mucositis during induction cycles with combined chemotherapy and rituximab was 31% and 26%, respectively. The 3-year event-free survival (EFS)/overall survival (OS) was 90% (95% confidence interval [CI], 76-96%) in the entire cohort and 93% (95% CI, 61-99%) in patients with CNS disease. Based on the results of this trial, an international randomized study of FAB/LMB 96 chemotherapy ± rituximab for high-risk patients is currently under investigation.

AB - Children and adolescents with Burkitt Lymphoma (BL) and combined central nervous system (CNS) and bone marrow involvement still have a poor prognosis with chemotherapy alone. We therefore investigated in children and adolescents with bone marrow (≥25% blasts) and/or CNS-positive Burkitt lymphoma the chemoimmunotherapy combination of rituximab (375 mg/m2) and the standard chemotherapy arm of our previously reported French-American-British (FAB) Lymphome Malins de Burkitt (LMB) 96 trial. Central pathological and cytogenetic characterization was also performed. There were 40 evaluable patients with Burkitt histology (25 with leukaemia and 15 with CNS disease ± leukaemia). The chemoimmunotherapy regimen was well tolerated. The incidence of grade III/IV mucositis during induction cycles with combined chemotherapy and rituximab was 31% and 26%, respectively. The 3-year event-free survival (EFS)/overall survival (OS) was 90% (95% confidence interval [CI], 76-96%) in the entire cohort and 93% (95% CI, 61-99%) in patients with CNS disease. Based on the results of this trial, an international randomized study of FAB/LMB 96 chemotherapy ± rituximab for high-risk patients is currently under investigation.

KW - Burkitt leukaemia

KW - Burkitt lymphoma

KW - Chemotherapy

KW - Children

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84912027747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912027747&partnerID=8YFLogxK

U2 - 10.1111/bjh.13040

DO - 10.1111/bjh.13040

M3 - Article

C2 - 25066629

AN - SCOPUS:84912027747

SN - 0007-1048

VL - 167

SP - 394

EP - 401

JO - British journal of haematology

JF - British journal of haematology

IS - 3

ER -

Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: A Children's Oncology Group Report

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this